皓元医药：2025年上半年，公司境外收入达5.6亿元

Core Viewpoint - The company, Haoyuan Pharmaceutical, is actively expanding its global presence and enhancing its operational efficiency, as evidenced by its recent performance and strategic initiatives [1] Group 1: Business Operations - The company has established 8 business centers, 6 research centers, and 4 production bases across various regions including China, the USA, Europe, India, Hong Kong, Japan, South Korea, and Southeast Asia [1] - The company utilizes a cross-regional collaboration mechanism between domestic professionals and international business personnel to quickly respond to the needs of over 10,000 global clients [1] Group 2: Partnerships and Collaborations - The company has formed partnerships with multiple multinational pharmaceutical giants, renowned global universities, research institutions, and CRO companies [1] - Stable collaborations have been established with numerous well-known overseas distributors specializing in drug research reagents [1] Group 3: Revenue Performance - In the first half of 2025, the company's overseas revenue reached 560 million yuan, representing a year-on-year growth of 39.8% [1] - Overseas revenue accounted for 43.0% of the main business income, an increase of nearly 5 percentage points compared to the previous year [1] - The company has achieved same-day order and next-day delivery in most regions of the USA and China, providing a convenient purchasing experience that outperforms imported brands [1]